Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1626 1628 1657 1672
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18269510 | COMPOUND, COMPOSITION, BIOTISSUE EMBRITTLEMENT AGENT, BIOTISSUE SURFACE DETACHMENT METHOD, AND BIOTISSUE DETACHMENT KIT | Non-Final OA | JUNTENDO EDUCATIONAL FOUNDATION |
| 18438385 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18608354 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | Non-Final OA | GEORGETOWN UNIVERSITY |
| 18555822 | AGENT FOR PROMOTING LIPID REDUCTION | Non-Final OA | MITSUBISHI GAS CHEMICAL COMPANY, INC. |
| 18428639 | Methods for Restoring Sensitivity to TTFields in TTFields-Resistant Cancer Cells with PTGER3 Inhibitors | Non-Final OA | Novocure GmbH |
| 18665333 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | Non-Final OA | Qpex Biopharma, Inc. |
| 17758427 | CICLESONIDE FOR AMELIORATING QUALITY OF LIFE (QOL) IN EQUINES | Final Rejection | Boehringer Ingelheim Vetmedica GmbH |
| 18231114 | AUTOIMMUNE THERAPY | Final Rejection | LDN Pharma Limited |
| 18537308 | TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS | Non-Final OA | OPKO HEALTH, INC. |
| 17308153 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | Final Rejection | MURRAY AND POOLE ENTERPRISES LTD |
| 18566093 | CANNABIDIOL FOR USE IN THE TREATMENT OF PAIN RESULTING FROM AN INDOLEAMINE 2,3-DIOXYGENASE-1 (IDO1) RELATED DISEASE | Non-Final OA | Assistance Publique - Hopitaux de Paris |
| 18563234 | AMINO ACIDS BEARING A TETRAZINE MOIETY | Non-Final OA | VALANX Biotech GmbH |
| 18551157 | TREATMENT OF HIDRADENITIS SUPPURATIVA WITH ORISMILAST | Non-Final OA | UNION THERAPEUTICS A/S |
| 18463439 | KRAS INHIBITOR AND PHARMACEUTICAL USES THEREOF | Non-Final OA | RISEN (SUZHOU) PHARMA TECH CO., LTD. |
| 18464725 | COMPOSITIONS AND METHODS FOR REVERSING AGE-ASSOCIATED DENDRITIC SPINE LOSS | Non-Final OA | UNIVERSITY OF PITTSBURGH MEDICAL CENTER |
| 18244773 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS | Final Rejection | Kissei Pharmaceutical Co., Ltd. |
| 18237837 | ADJUVANT THERAPY FOR USE IN PROSTATE CANCER TREATMENT | Non-Final OA | FUND SA |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | Final Rejection | Rush University Medical Center |
| 18324306 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | Non-Final OA | GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITATS |
| 18178703 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS | Final Rejection | UNIVERSITATSSPITAL BASEL |
| 18099654 | ANIMAL STERILIZATION BY ESTROGENIC COMPOUNDS | Non-Final OA | Insigna Inc. |
| 18069006 | ANALGESIC FORMULATIONS AND METHODS FOR REDUCED POSTOPERATIVE NAUSEA AND VOMITING AND ENHANCED POSTOPERATIVE PAIN RELIEF | Final Rejection | Hutchison Health, LLC |
| 17757924 | DIHYDROERGOTAMINE MESYLATE FORMULATIONS AND PRE-FILLED INJECTORS FOR THERAPEUTIC DELIVERY OF THE SAME | Final Rejection | Scienture, LLC |
| 17894333 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | Non-Final OA | Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou |
| 17790891 | COMPOSITION COMPRISING LISURIDE COMPOUND FOR TREATING FRAGILE X SYNDROME OR RELATED DEVELOPMENTAL DISORDERS | Final Rejection | NEUROVENTI |
| 17707496 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | Final Rejection | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE |
| 17640785 | MAGL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | LUNAN PHARMACEUTICAL GROUP CORPORATION |
| 17670278 | Combination Treatment for Hematological Cancers | Non-Final OA | Geron Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy